A Phase 2/3 interventional study of Izokibep and Placebo to izokibep in Psoriatic Arthritis, sponsored by ACELYRIN Inc.. Terminated at 71 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-23.
Sponsored by ACELYRIN Inc. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 194 studies in Arthritis, Psoriatic with a site in United States — 30 open to participants now, 60 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 194 studies in Arthritis, Psoriatic with a site in United States, this one is the 65th largest by enrollment of the 159 interventional ones that give a count, is one of 11 that started in 2022, is one of 2 in phase 2/3, and was the 148th registered.
602 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →30 of the 194 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 89 Arthritis, Psoriatic studies recruiting now, 52 (58%) set no upper age limit and 28 (31%) stop at 75 or younger; 12 take children under 18; 14 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
194 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 351 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 228 across the 159 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 194 have an industry lead sponsor. The 10 most frequent:
ACELYRIN Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 3 (50%) have results posted.
ACELYRIN Inc. has 2 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
17 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 17 to your calendar (.ics) → With an account.
Among the 194 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA).
This study will evaluate the efficacy of izokibep in subjects with PsA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
General
Type of Subject and Disease Characteristics
Subject must have had an inadequate response, intolerance, or to at least one of the following:
Other Inclusions
Exclusion Criteria:
Disease-related Medical Conditions
OR
Any of the following symptoms (of unknown etiology) or any signs or symptoms within the last year that in the opinion of the Investigator may be suggestive of IBD, with fecal calprotectin ≥ 500 μg/g; OR if fecal calprotectin >150 to \<500 μg/g without confirmed approval from a GI consult that an IBD diagnosis is clinically unlikely when the following clinical signs and symptoms are present:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo from Day 1/Week 0 to Week 15, then izokibep from Week 16 to Week 51
Drug: Izokibep · Drug: Placebo to izokibep
Izokibep Dose 1 from Day 1/Week 0 to Week 51
Drug: Izokibep
Izokibep Dose 2 from Day 1/Week 0 to Week 51
Drug: Izokibep · Drug: Placebo to izokibep
Izokibep Dose 3 from Day 1/Week 0 to Week 51
Drug: Izokibep · Drug: Placebo to izokibep
Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC)
Form: Solution for injection Route of administration: Subcutaneous (SC)
Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16
ACR50 is a clinical trial measure for PsA, indicating a 50% improvement in symptoms. To qualify, participants must show a 50% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR50 is binary-patients either meet it or not.
Time frame: Week 16
Number of Participants With Baseline ≥ 3% Body Surface Area (BSA) Psoriasis Who Achieved a 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI90) at Week 16
PASI is a tool used in clinical trials to measure the severity and extent of psoriasis. Scores range from a minimum of 0 to a maximum of 72, with higher scores indicating more severe disease.
Time frame: Baseline and Week 16
Number of Participants With Baseline Enthesitis > 0 With Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) at Week 16
LEI is a clinical tool used to assess enthesitis in conditions like psoriatic arthritis and spondyloarthritis. It evaluates six sites: bilateral lateral epicondyles, medial femoral condyles, and achilles tendons. Each site is scored 0 (no pain) or 1 (pain on pressure), with a total score ranging from a minimum of 0 to a maximum of 6, where higher scores indicate more severe enthesitis.
Time frame: Baseline and Week 16
Number of Participants Achieving Minimal Disease Activity (MDA) at Week 16
A participants was classified as being in MDA when at least five of the following seven criteria were met: * Tender joint count based on 68 joints (TJC68) ≤ 1 * Swollen joint count based on 66 joints (SJC66) ≤ 1 * PASI ≤ 1 or BSA ≤ 3% * Participant's Pain Assessment (Visual Analogue Scale \[VAS\]) ≤ 15 mm * Participant's Global Activity VAS ≤ 20 mm (corresponding to participant's Global Assessment of Disease Activity) * Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 * Tender enthesitis points ≤ 1 out of 6 sites assessed by the LEI.
Time frame: Week 16
Number of Participants Achieving 20% Improvement in ACR (ACR20) at Week 16
ACR20 is a clinical trial measure for PsA, indicating a 20% improvement in symptoms. To qualify, participants must show a 20% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR20 is binary-patients either meet it or not.
Time frame: Week 16
Number of Participants With Baseline Psoriatic Arthritis Impact of Disease (PsAID) Score ≥ 3 With Improvement in PsAID Score at Week 16
The PsAID consists of nine items, each scored on a numeric rating scale (0-10), covering key aspects of disease burden, including pain, fatigue, skin problems, work/leisure activities, functional capacity, sleep disturbance, anxiety, coping, and social participation. The total score is calculated as a weighted sum of these individual items, with higher scores indicating a greater impact of the disease. The minimum score is 0 (no disease impact), while the maximum is 10 (worst possible disease impact). Reaching an improvement was considered an increase of 3 units from baseline score.
Time frame: Week 16
Change in Physical Function as Assessed by HAQ-DI From Baseline to Week 16
The HAQ-DI consists of 20 questions divided into eight categories: dressing, arising, eating, walking, hygiene, reaching, grip, and other activities. Each item is scored on a scale from 0 to 3, where 0 = no difficulty, 1 = some difficulty, 2 = much difficulty, and 3 = unable to perform. The final HAQ-DI score is calculated as the average of the highest scores in each category, resulting in a range from 0 (no disability) to 3 (severe disability). Higher scores indicate greater functional impairment. A negative change indicates an improvement in functional impairment.
Time frame: Baseline and Week 16
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and AE of Special Interest During Period 1
An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.
Time frame: Up to Week 16, or 4 weeks after participant's last dose in case of treatment discontinuation
Number of Participants Who Experienced TEAEs, Serious TEAEs and AE of Special Interest During Period 2
An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.
Time frame: First dose of study treatment on or after Week 16 up to Week 55
Number of Participants With a Positive Treatment-emergent Anti-drug Antibody (ADA) Result
Blood samples were collected at different timepoints throughout the study. ADA is considered "Positive" if any titer value is available.
Time frame: Baseline to Week 65
A total of 351 participants with Psoriatic Arthritis (PsA) symptoms were recruited in Canada, United States, Bulgaria, Czech Republic, Germany, Hungary, Poland, and Spain between November 2022 and August 2024.
| Milestone | Period 1: Placebo QW ; Period 2: Izokibep 160 mg QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Started | 118 | 8 | 113 | 112 |
| Completed period 1 | 114 | 8 | 111 | 105 |
| Completed | 64 | 4 | 57 | 52 |
| Not completed | 54 | 4 | 56 | 60 |
| Withdrew: Withdrawal by subject | 14 | 0 | 9 | 20 |
| Withdrew: Lost to follow-up | 3 | 0 | 7 | 2 |
| Withdrew: Termination of study by sponsor | 37 | 4 | 40 | 38 |
ACR50 is a clinical trial measure for PsA, indicating a 50% improvement in symptoms. To qualify, participants must show a 50% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR50 is binary-patients either meet it or not.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Number of Participants Who Achieved 50% Improvement in American College of Rheumatology (ACR50) at Week 16 | 18 | 4 | 49 | 45 |
PASI is a tool used in clinical trials to measure the severity and extent of psoriasis. Scores range from a minimum of 0 to a maximum of 72, with higher scores indicating more severe disease.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Number of Participants With Baseline ≥ 3% Body Surface Area (BSA) Psoriasis Who Achieved a 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI90) at Week 16 | 7 | 3 | 37 | 38 |
LEI is a clinical tool used to assess enthesitis in conditions like psoriatic arthritis and spondyloarthritis. It evaluates six sites: bilateral lateral epicondyles, medial femoral condyles, and achilles tendons. Each site is scored 0 (no pain) or 1 (pain on pressure), with a total score ranging from a minimum of 0 to a maximum of 6, where higher scores indicate more severe enthesitis.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Number of Participants With Baseline Enthesitis > 0 With Resolution of Enthesitis (Leeds Enthesitis Index [LEI] = 0) at Week 16 | 35 | 4 | 38 | 30 |
A participants was classified as being in MDA when at least five of the following seven criteria were met: * Tender joint count based on 68 joints (TJC68) ≤ 1 * Swollen joint count based on 66 joints (SJC66) ≤ 1 * PASI ≤ 1 or BSA ≤ 3% * Participant's Pain Assessment (Visual Analogue Scale \[VAS\]) ≤ 15 mm * Participant's Global Activity VAS ≤ 20 mm (corresponding to participant's Global Assessment of Disease Activity) * Health Assessment Questionnaire-Disability Index (HAQ-DI) ≤ 0.5 * Tender enthesitis points ≤ 1 out of 6 sites assessed by the LEI.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Number of Participants Achieving Minimal Disease Activity (MDA) at Week 16 | 17 | 3 | 47 | 46 |
ACR20 is a clinical trial measure for PsA, indicating a 20% improvement in symptoms. To qualify, participants must show a 20% reduction in tender and swollen joint counts plus improvements in three of five additional criteria, including pain, global assessments, physical function, and inflammatory markers. ACR20 is binary-patients either meet it or not.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Number of Participants Achieving 20% Improvement in ACR (ACR20) at Week 16 | 41 | 6 | 72 | 66 |
The PsAID consists of nine items, each scored on a numeric rating scale (0-10), covering key aspects of disease burden, including pain, fatigue, skin problems, work/leisure activities, functional capacity, sleep disturbance, anxiety, coping, and social participation. The total score is calculated as a weighted sum of these individual items, with higher scores indicating a greater impact of the disease. The minimum score is 0 (no disease impact), while the maximum is 10 (worst possible disease impact). Reaching an improvement was considered an increase of 3 units from baseline score.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Number of Participants With Baseline Psoriatic Arthritis Impact of Disease (PsAID) Score ≥ 3 With Improvement in PsAID Score at Week 16 | 12 | 3 | 43 | 40 |
The HAQ-DI consists of 20 questions divided into eight categories: dressing, arising, eating, walking, hygiene, reaching, grip, and other activities. Each item is scored on a scale from 0 to 3, where 0 = no difficulty, 1 = some difficulty, 2 = much difficulty, and 3 = unable to perform. The final HAQ-DI score is calculated as the average of the highest scores in each category, resulting in a range from 0 (no disability) to 3 (severe disability). Higher scores indicate greater functional impairment. A negative change indicates an improvement in functional impairment.
| Score on scale | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Change in Physical Function as Assessed by HAQ-DI From Baseline to Week 16 | -0.14 (-0.23 to -0.06) | -0.03 (-0.35 to 0.28) | -0.30 (-0.39 to -0.21) | -0.31 (-0.40 to -0.22) |
An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.
| Participants | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| TEAEs | 48 | 6 | 76 | 82 |
| Serious TEAEs | 1 | 2 | 2 | 3 |
| AEs of Special Interest | 2 | 1 | 5 | 6 |
An AE was any untoward medical occurrence in a participant, regardless of a causal relationship with the study treatment. TEAEs included any event occurring after the participant received study treatment. Clinically significant changes in vital signs, electrocardiograms and laboratory tests recorded after treatment administration were documented as TEAEs. TEAEs were considered serious if they led to death, were life-threatening, required hospitalization or its prolongation, caused disability, resulted in congenital anomalies or were considered medically important. The events of special interest monitored were : candida infection; inflammatory bowel disease; suicidal ideation; malignancies; major adverse cardiovascular and cerebrovascular events (cerebrovascular accident and transient ischemic attack, nonfatal myocardial infarction or unstable angina, cardiovascular death); tuberculosis; infections (opportunistic, serious, or fungal); cytopenia; systemic hypersensitivity reactions.
| Participants | Period 2: Placebo/Izokibep 160 mg QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| TEAEs | 89 | 5 | 67 | 67 |
| Serious TEAEs | 4 | 1 | 7 | 2 |
| AEs of Special Interest | 3 | 1 | 5 | 2 |
Blood samples were collected at different timepoints throughout the study. ADA is considered "Positive" if any titer value is available.
| Participants | Period 1: Placebo QW; Period 2: Izokibep 160 mg QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|
| Baseline | 56 | 4 | 57 | 54 |
| Week 2 | 56 | 3 | 61 | 54 |
| Week 4 | 56 | 4 | 58 | 55 |
| Week 12 | 53 | 2 | 55 | 51 |
| Week 16 | 54 | 6 | 57 | 57 |
| Week 24 | 40 | 5 | 70 | 75 |
| Week 36 | 62 | 7 | 67 | 76 |
| Week 52 | 65 | 7 | 63 | 68 |
| Follow-up Visit - Week 59 | 76 | 6 | 67 | 77 |
| End of Study - Week 65 | 49 | 2 | 31 | 40 |
Collected over For Placebo QW - Period 1: Up to Week 16, or 4 weeks after participant's last dose in case of treatment discontinuation. A TEAE that occurred before the first dose of study drug in Period 2 and is within 28 days after the end of study drug in Period 1 is assigned to Period 1. For Placebo/Izokibep 160 mg QW - Period 2: From Week 16 up to Week 55. For Izokibep 80 mg Q4W, Izokibep 160 mg Q2W, Izokibep 160 mg QW: Up to Week 55.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QW - Period 1 | 0/118 (0%) | 1/118 (0.8%) | 9/118 (7.6%) |
| Placebo/Izokibep 160 mg QW - Period 2 | 0/114 (0%) | 4/114 (3.5%) | 65/114 (57%) |
| Izokibep 80 mg Q4W | 0/8 (0%) | 2/8 (25%) | 6/8 (75%) |
| Izokibep 160 mg Q2W | 0/113 (0%) | 8/113 (7.1%) | 78/113 (69%) |
| Izokibep 160 mg QW | 0/112 (0%) | 4/112 (3.6%) | 84/112 (75%) |
| Event | Placebo QW - Period 1 | Placebo/Izokibep 160 mg QW - Period 2 | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|---|
| Angina unstableCardiac disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Coronary artery diseaseCardiac disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Supraventricular tachycardiaCardiac disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Atrial fibrillationCardiac disorders | 0/118 | 0/114 | 0/8 | 1/113 | 1/112 |
| InflammationGeneral disorders | 0/118 | 0/114 | 0/8 | 0/113 | 1/112 |
| Systemic inflammatory response syndromeGeneral disorders | 0/118 | 0/114 | 0/8 | 0/113 | 1/112 |
| CellulitisInfections and infestations | 0/118 | 0/114 | 0/8 | 0/113 | 1/112 |
| PneumoniaInfections and infestations | 0/118 | 0/114 | 0/8 | 0/113 | 1/112 |
| Hepatic enzyme increasedInvestigations | 0/118 | 0/114 | 0/8 | 0/113 | 1/112 |
| Event | Placebo QW - Period 1 | Placebo/Izokibep 160 mg QW - Period 2 | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW |
|---|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 0/118 | 53/114 | 2/8 | 52/113 | 65/112 |
| Injection site pruritusGeneral disorders | 1/118 | 27/114 | 2/8 | 25/113 | 29/112 |
| Upper respiratory tract infectionInfections and infestations | 4/118 | 6/114 | 2/8 | 10/113 | 20/112 |
| NasopharyngitisInfections and infestations | 0/118 | 14/114 | 0/8 | 18/113 | 13/112 |
| Coronary artery diseaseCardiac disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Angina unstableCardiac disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Supraventricular tachycardiaCardiac disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| DiarrhoeaGastrointestinal disorders | 0/118 | 7/114 | 1/8 | 4/113 | 3/112 |
| Tooth disorderGastrointestinal disorders | 0/118 | 0/114 | 1/8 | 0/113 | 0/112 |
| Injection site swellingGeneral disorders | 0/118 | 13/114 | 1/8 | 13/113 | 13/112 |
Full Analysis Set: all participants randomized who received at least one administration of test material was included in the summaries and analyses.
| Age, Continuous(Years) | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW | Total |
|---|---|---|---|---|---|
| Mean | 52.6 ± 11.74 | 63.1 ± 9.40 | 49.5 ± 13.26 | 51.8 ± 12.20 | 51.6 ± 12.49 |
| Sex: Female, Male(Participants) | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW | Total |
|---|---|---|---|---|---|
| Female | 67 | 5 | 46 | 48 | 166 |
| Male | 51 | 3 | 67 | 64 | 185 |
| Ethnicity (NIH/OMB)(Participants) | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 13 | 1 | 14 | 7 | 35 |
| Not Hispanic or Latino | 105 | 7 | 99 | 104 | 315 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race/Ethnicity, Customized(participants) | Period 1: Placebo QW | Izokibep 80 mg Q4W | Izokibep 160 mg Q2W | Izokibep 160 mg QW | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 3 | 0 | 2 | 1 | 6 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 0 | 2 | 2 | 7 |
| White | 110 | 8 | 108 | 109 | 335 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Other | 2 | 0 | 1 | 0 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Nov 2022 to primary completion in Nov 2023, 12 months.
Results were first posted in May 2025, 1 year 5 months after primary completion. A results delay was requested in Nov 2024.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Izokibep
ACELYRIN Inc.